, , ,

As a mental health therapst, I read a lot and try to stay abreast of different treatment options that may or may not be helpful to my clients.  I read an article published in the Medical News Today on March 8, 2019 that was very well written by Catharine Paddock PhD and fact checked by Jasmin Collier.  The article is titled: “The FDA approve esketamine nasal spray for severe depression”.

The author covered important things.  She gave the name of the company that is making the drug as a nasal spray.  She stated that the spray is to be used in conjunction with an oral antidepressant by adults with treatment-resistent depression.  The article stated “The most common side effects the teams observed in the trials included dizziness, disassociation, sedation, vertigo, nausea, vomiting, anxiety, lethargy, decreased sensitivity, raised blood pressure, and a feeling of intoxication.”

She noted that due to the risks involved with the use of this drug, which also includes “abuse and misuse”, it will be closely monitored. The article states: “the drug will only be available through a restricted distribution system, and it must be administered in a certified medical office where the healthcare provider can monitor the patient.”  Users will not be allowed to take any of this medication home.

I am providing a link to the full article so you may read it for yourself.  I would like to know what you think of this treatment and its possibilities.  Please leave a comment on this post.